2型糖尿病患者抗动脉粥样硬化的临床研究进展  

Clinical Progress of Antiatherosclerosis in Patients with Type 2 Diabetes

作　　者：任忠法[1] 薛现中[1] 官庆波[1] 

机构地区：[1]山东省滕州市中心人民医院内分泌科

出　　处：《医学综述》2009年第11期1696-1698,共3页Medical Recapitulate

摘　　要：糖尿病发病率逐年上升,糖尿病与动脉粥样硬化关系密切,糖尿病动脉粥样硬化的发病机制十分复杂,研究证实基质金属蛋白酶9与氧化低密度脂蛋白与糖尿病动脉粥样硬化关系密切。高血糖状态下,基质金属蛋白酶9与氧化低密度脂蛋白水平增加,是糖尿病动脉粥样硬化的主要原因,应用药物干预可降低其水平,逆转其对组织的损伤,阻止或者延缓糖尿病动脉粥样硬化的发生、发展,彩色多普勒超声可发现糖尿病动脉粥样硬化早期病变。本文就基质金属蛋白酶9与氧化低密度脂蛋白与动脉硬化的关系及吡格列酮降糖外的抗动脉硬化作用及彩色多普勒早期检测动脉粥样硬化病变进行综述。The incidence rate of diabetes is increasing year by year, it has close relationship with atherosclerosis. The pathogenesis of Diabetic Atheroaclerosis is very complicated. In the meanwhile, It is shown that Diabetic Atheresclerosis is closely related to Matrix Metallopreteinase-9 （MMP-9） ,oxside Low Density Lipopro- rein （ox-LDL）. The level of MMP-9 and ox-LDL is increased under hyperglyeosemia, which is the main factor resulting in atheresclerosis. The related drug intervention can decrease its level, turn the tissue damage over, inhibit or postpone the genesis and development of diabetic atherosclerosis. Color Doppler Uhrasonography can detect its early pathological changes. This article reviews the relationship of atherosclerosis with MMP-9 and ox- LDL, the antiatherosclerostic effect of pioglitazone besides suger-lowering, and early detection of atheroselerosis by color Doppler.

关 键 词：糖尿病 动脉粥样硬化 基质金属蛋白酶9 氧化低密度脂蛋白 吡格列酮 彩色多普勒 

分 类 号：R587.2[医药卫生—内分泌]